Also trades as: 0HB0.L (LSE) · $vol 0M
AGIO NASDAQ
Agios Pharmaceuticals, Inc.
1W: +1.4%
1M: -1.8%
3M: +17.0%
YTD: +23.6%
1Y: -5.8%
3Y: +26.5%
5Y: -27.6%
$33.60
-0.04 (-0.12%)
Weekly Expected Move ±4.8%
$30
$32
$34
$35
$37
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider—
Congress3 trades
ETF Holdings—
Key Statistics
Market Cap$2.0B
52W Range22.24-46
Volume750,164
Avg Volume1,048,388
Beta0.60
Dividend—
Analyst Ratings
Company Info
CEOBrian Goff
Employees540
SectorHealthcare
IndustryBiotechnology
IPO Date2013-07-24
Websiteagios.com
88 Sidney Street
Cambridge, MA 02139
US
Cambridge, MA 02139
US
617 649 8600
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Latest News
AXQ Capital LP Acquires Shares of 27,656 Agios Pharmaceuticals, Inc. $AGIO
Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?
Bank of New York Mellon Corp Invests $7.37 Million in Agios Pharmaceuticals, Inc. $AGIO
Assenagon Asset Management S.A. Has $3.86 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO
AGIO Q2 Earnings Beat Estimates, Revenues Increase Year Over Year
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Gheuens Sarah | S-Sale | 30,000 | $30.48 | 2026-08-04 |
| Backstrom Jay T. | A-Award | 1,447 | — | 2026-07-08 |
| Backstrom Jay T. | M-Exempt | 1,447 | — | 2026-07-08 |
| Gheuens Sarah | M-Exempt | 8,375 | — | 2026-07-01 |
| Gheuens Sarah | S-Sale | 4,007 | $37.56 | 2026-07-01 |